

Consumer Healthcare turnover

Three months ended 30 June 2013

	Total		
	£m	CER%	AR%
Turnover			
Total wellness	468	(7)	(4)
Oral care	481	8	9
Nutrition	291	7	7
Skin health	69	11	13
Total	<u>1,309</u>	<u>2</u>	<u>3</u>

	Total		
	£m	CER%	AR%
Turnover			
US	238	5	8
Europe	463	(2)	1
ROW	608	4	2
Total	<u>1,309</u>	<u>2</u>	<u>3</u>

Six months ended 30 June 2013

	Total		
	£m	CER%	AR%
Turnover			
Total wellness	984	(6)	(4)
Oral care	961	6	6
Nutrition	571	6	6
Skin health	140	9	10
Total	<u>2,656</u>	<u>1</u>	<u>1</u>

	Total		
	£m	CER%	AR%
Turnover			
US	476	4	6
Europe	911	(3)	(2)
ROW	1,269	4	2
Total	<u>2,656</u>	<u>1</u>	<u>1</u>

Pharmaceuticals and Vaccines turnover – Three months ended 30 June 2013

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	1,905	4	5	930	8	11	494	(2)	2	234	9	10	247	(3)	(12)
<i>Avamys/Veramyst</i>	60	(6)	(6)	12	(20)	(20)	23	5	15	17	6	6	8	(23)	(38)
<i>Flixonase/Flonase</i>	27	(13)	(13)	1	(50)	(50)	9	-	-	15	-	-	2	(60)	(60)
<i>Flixotide/Flovent</i>	202	5	7	124	12	16	29	(13)	(6)	14	-	-	35	3	(5)
<i>Seretide/Advair</i>	1,358	5	7	708	8	10	376	(1)	3	117	14	17	157	4	(4)
<i>Serevent</i>	33	(13)	(13)	12	-	(8)	14	(13)	(13)	1	-	-	6	(44)	(33)
<i>Ventolin</i>	160	7	9	69	18	21	32	-	7	44	-	-	15	-	(6)
<i>Xyzal</i>	24	(13)	(25)	-	-	-	-	-	-	5	50	25	19	(21)	(32)
<i>Zyrtec</i>	17	6	(6)	-	-	-	-	-	-	12	38	50	5	(20)	(50)
Other*	24	-	(8)	4	-	33	11	(8)	(15)	9	(17)	(25)	-	-	100
Anti-virals	158	(17)	(20)	5	(62)	(62)	17	(20)	(15)	87	(3)	-	49	(25)	(36)
<i>Hepsera</i>	31	(3)	(3)	-	-	-	-	-	-	24	(8)	-	7	13	(13)
<i>Zovirax</i>	55	(9)	(17)	9	-	13	7	(30)	(30)	10	11	11	29	(10)	(26)
<i>Valtrex</i>	20	-	(9)	-	-	-	5	(17)	(17)	8	-	-	7	29	-
<i>Zeffix</i>	55	(12)	(8)	4	-	-	3	(25)	(25)	44	(11)	(4)	4	(17)	(33)
Other*	(3)	<(100)	<(100)	(8)	-	-	2	-	-	1	-	-	2	(100)	(88)
Central nervous system	373	(15)	(17)	103	(26)	(24)	90	(13)	(9)	87	7	7	93	(18)	(29)
<i>Imigran/Imitrex</i>	47	(8)	(10)	19	(14)	(14)	16	(11)	(11)	2	(50)	-	10	20	-
<i>Lamictal</i>	133	(8)	(10)	63	(18)	(17)	27	(10)	(7)	20	5	5	23	17	-
<i>Requip</i>	29	(30)	(34)	1	(83)	(83)	13	(37)	(32)	3	(25)	(25)	12	-	(20)
<i>Seroxat/Paxil</i>	79	(24)	(29)	-	-	-	15	(7)	-	21	-	(5)	43	(35)	(43)
<i>Wellbutrin</i>	24	15	20	4	-	-	13	8	8	8	14	14	(1)	<(100)	<(100)
Other*	61	(18)	(15)	16	(50)	(50)	6	(17)	-	33	22	22	6	(29)	(14)
Cardiovascular and urogenital	594	2	4	335	-	2	136	-	5	79	7	10	44	14	-
<i>Arixtra</i>	45	(9)	(4)	13	(13)	(13)	21	(17)	(13)	9	14	29	2	100	100
<i>Avodart</i>	221	12	12	84	1	4	68	10	17	27	35	35	42	26	11
<i>Coreg</i>	33	(6)	(6)	33	(9)	(6)	-	-	-	-	-	-	-	-	-
<i>Fraxiparine</i>	61	-	3	-	-	-	38	(10)	(3)	24	20	20	(1)	-	-
<i>Lovaza</i>	161	-	3	161	-	3	-	-	-	-	-	-	-	-	-
Other*	73	(9)	(5)	44	10	13	9	25	13	19	(28)	(24)	1	<(100)	(80)
Metabolic	45	2	-	-	-	-	11	43	57	18	12	6	16	(23)	(27)
Other*	45	2	-	-	-	-	11	43	57	18	12	6	16	(23)	(27)
Anti-bacterials	309	1	2	8	75	100	87	(13)	(7)	199	9	9	15	(18)	(32)
<i>Augmentin</i>	150	-	1	-	-	-	45	(13)	(6)	99	11	10	6	(36)	(45)
Other*	159	2	3	8	75	100	42	(13)	(9)	100	6	8	9	-	(18)
Oncology and emesis	233	17	19	91	10	12	80	26	31	36	23	20	26	13	8
<i>Arzerra</i>	17	20	13	10	22	11	7	17	17	-	-	-	-	-	-
<i>Promacta</i>	45	53	50	19	38	46	13	50	63	5	67	67	8	83	33
<i>Tyverb/Tykerb</i>	53	(12)	(12)	15	(18)	(12)	21	(5)	(5)	11	(21)	(21)	6	-	(14)
<i>Votrient</i>	79	97	>100	36	70	80	30	100	>100	9	>100	>100	4	>100	>100
Other*	39	(31)	(25)	11	(45)	(50)	9	(18)	(18)	11	22	22	8	(60)	(20)
Dermatology	206	(3)	(2)	38	(37)	(36)	44	14	22	109	12	14	15	-	(21)
<i>Bactroban</i>	24	(20)	(20)	5	(62)	(62)	6	-	-	11	10	10	2	100	100
<i>Duac</i>	18	(22)	(22)	3	(73)	(73)	7	75	75	4	33	33	4	(20)	(20)
Other*	164	3	4	30	(17)	(14)	31	8	19	94	12	13	9	(8)	(31)
Rare diseases	127	21	15	29	53	53	32	(3)	3	12	20	20	54	24	8
<i>Volibris</i>	37	23	19	-	-	-	20	11	11	2	50	-	15	36	36
<i>Flolan</i>	28	(11)	(20)	7	(13)	(13)	5	(43)	(29)	-	-	-	16	-	(20)
Other*	62	45	41	22	100	100	7	-	17	10	13	25	23	42	21
Immuno-inflammation	38	>100	>100	35	>100	>100	2	-	-	-	-	-	1	-	-
<i>Benlysta</i>	38	>100	>100	35	>100	>100	2	-	-	-	-	-	1	-	-
Other pharmaceuticals	196	14	12	2	100	>100	37	-	3	97	(1)	(2)	60	33	25
Vaccines	786	-	3	214	14	17	264	5	10	247	(13)	(11)	61	(3)	(3)
<i>Boostrix</i>	68	16	17	41	8	11	19	38	46	5	67	67	3	(20)	(40)
<i>Cervarix</i>	46	(8)	(8)	2	100	100	13	(20)	(13)	25	19	19	6	(46)	(54)
<i>Fluarix, FluLaval</i>	7	40	40	2	100	100	(1)	50	50	5	-	25	1	-	(50)
Hepatitis	170	1	3	73	3	7	52	(4)	-	36	(3)	-	9	22	-
<i>Infanrix, Pediarix</i>	218	18	22	72	31	33	103	8	13	28	27	27	15	17	25
<i>Rotarix</i>	87	(8)	(6)	25	9	14	16	60	60	37	(23)	(21)	9	(29)	(36)
<i>Synflorix</i>	74	(31)	(27)	-	-	-	12	-	9	60	(37)	(33)	2	-	-
Other*	116	(2)	4	(1)	-	-	50	(2)	-	51	(7)	(6)	16	38	100
	4,970	2	3	1,790	5	8	1,294	-	5	1,205	2	3	681	(3)	(13)
ViiV Healthcare (HIV)	339	(4)	(2)												
	5,309	1	2												

Pharmaceuticals and Vaccines turnover – Six months ended 30 June 2013

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
Respiratory	3,841	5	5	1,850	8	10	983	(2)	-	448	8	9	560	6	(2)
<i>Avamys/Veramyst</i>	140	8	5	23	(21)	(21)	40	3	8	33	14	14	44	32	16
<i>Flixonase/Flonase</i>	66	(7)	(10)	3	(67)	(67)	17	-	-	28	8	8	18	(5)	(14)
<i>Flixotide/Flovent</i>	415	6	7	253	13	15	62	(8)	(5)	29	7	7	71	(3)	(7)
<i>Seretide/Advair</i>	2,667	5	6	1,396	8	10	746	(1)	1	223	11	13	302	4	(4)
<i>Serevent</i>	66	(13)	(13)	25	(4)	(4)	28	(15)	(15)	2	100	100	11	(31)	(31)
<i>Ventolin</i>	322	5	7	145	13	15	65	-	3	85	-	-	27	-	(4)
<i>Xyzal</i>	76	28	12	-	-	-	-	-	-	9	13	13	67	30	12
<i>Zyrtec</i>	41	7	(2)	-	-	-	-	-	-	21	24	24	20	(4)	(20)
Other*	48	(6)	(8)	5	(20)	-	25	(13)	(17)	18	(10)	(10)	-	-	100
Anti-virals	341	(8)	(10)	22	(13)	(8)	33	(24)	(21)	175	(1)	2	111	(10)	(22)
<i>Hepsera</i>	58	(5)	(5)	-	-	-	-	-	-	45	(7)	(2)	13	-	(13)
<i>Zovirax</i>	110	(8)	(15)	20	27	33	14	(30)	(30)	19	12	12	57	(13)	(26)
<i>Valtrex</i>	41	(7)	(11)	1	(50)	(50)	10	(17)	(17)	17	-	-	13	-	(13)
<i>Zeffix</i>	112	(7)	(5)	7	17	17	6	(33)	(33)	91	(4)	-	8	(17)	(33)
Other*	20	(19)	(26)	(6)	<(100)	<(100)	3	100	>100	3	>100	>100	20	(8)	(17)
Central nervous system	735	(12)	(13)	215	(19)	(17)	182	(12)	(9)	169	9	9	169	(17)	(27)
<i>Imigran/Imitrex</i>	95	-	(1)	41	11	11	33	(9)	(6)	4	-	33	17	(5)	(19)
<i>Lamictal</i>	266	(9)	(10)	129	(21)	(19)	55	(7)	(5)	39	8	8	43	20	5
<i>Requip</i>	60	(29)	(33)	3	(80)	(80)	28	(33)	(30)	7	-	-	22	(4)	(19)
<i>Seroxat/Paxil</i>	152	(20)	(25)	-	-	-	29	(3)	-	44	5	5	79	(32)	(40)
<i>Wellbutrin</i>	48	18	20	9	100	>100	25	9	14	15	15	15	(1)	(100)	<(100)
Other*	114	(10)	(9)	33	(27)	(25)	12	(29)	(29)	60	13	11	9	(20)	(10)
Cardiovascular and urogenital	1,152	(12)	(11)	648	(22)	(21)	269	-	3	150	6	7	85	16	5
<i>Arixtra</i>	94	(3)	(1)	30	(3)	(3)	44	(10)	(8)	17	23	31	3	-	-
<i>Avodart</i>	424	11	11	159	(1)	1	134	15	19	51	28	28	80	22	10
<i>Coreg</i>	66	(7)	(6)	65	(9)	(7)	-	-	-	-	-	-	1	-	-
<i>Fraxiparine</i>	113	(8)	(6)	-	-	-	71	(15)	(11)	43	5	8	(1)	-	-
<i>Lovaza</i>	309	(2)	-	308	(2)	-	-	-	-	-	-	-	1	-	-
Other*	146	(56)	(55)	86	(67)	(66)	20	5	5	39	(17)	(17)	1	(100)	(75)
Metabolic	90	19	15	1	>100	>100	20	46	54	36	16	13	33	(22)	(28)
Other*	90	19	15	1	>100	>100	20	46	54	36	16	13	33	(22)	(28)
Anti-bacterials	648	4	4	13	20	30	206	(7)	(4)	395	12	12	34	(12)	(19)
<i>Augmentin</i>	325	8	8	-	-	-	107	(5)	(3)	202	18	17	16	(11)	(16)
Other*	323	1	1	13	20	30	99	(9)	(6)	193	7	7	18	(13)	(22)
Oncology and emesis	454	20	21	179	17	19	159	26	29	67	15	14	49	24	17
<i>Arzerra</i>	38	41	41	20	11	11	18	100	100	-	-	-	-	-	-
<i>Promacta</i>	85	51	49	35	42	46	24	44	50	10	100	100	16	58	33
<i>Tyverb/Tykerb</i>	105	(13)	(13)	30	(15)	(12)	42	(9)	(7)	21	(22)	(22)	12	-	(14)
<i>Votrient</i>	150	>100	>100	69	86	92	56	100	>100	16	>100	100	9	>100	>100
Other*	76	(25)	(23)	25	(33)	(36)	19	(27)	(27)	20	5	5	12	(40)	(20)
Dermatology	405	(4)	(4)	79	(35)	(33)	86	12	16	208	9	9	32	(10)	(20)
<i>Bactroban</i>	49	(18)	(18)	13	(46)	(46)	12	(8)	(8)	20	11	5	4	(25)	-
<i>Duac</i>	35	(31)	(31)	7	(74)	(74)	14	27	27	8	33	33	6	(14)	(14)
Other*	321	3	3	59	(15)	(12)	60	14	20	180	8	8	22	(7)	(24)
Rare diseases	240	17	11	56	34	37	63	(3)	-	21	11	11	100	24	8
<i>Volibris</i>	71	24	20	-	-	-	40	8	11	5	50	25	26	47	37
<i>FloLAN</i>	55	(16)	(21)	14	(13)	(13)	10	(36)	(29)	-	-	-	31	(10)	(23)
Other*	114	38	31	42	64	68	13	-	-	16	-	7	43	50	26
Immuno-inflammation	67	>100	>100	62	>100	>100	4	>100	>100	-	-	-	1	100	-
<i>Benlysta</i>	67	>100	>100	62	>100	>100	4	>100	>100	-	-	-	1	100	-
Other pharmaceuticals	337	(4)	(8)	1	-	-	56	(39)	(38)	183	(1)	(6)	97	23	20
Vaccines	1,466	(5)	(4)	360	7	9	501	5	8	472	(5)	(3)	133	(43)	(44)
<i>Boostrix</i>	114	7	9	62	5	7	32	24	28	9	13	13	11	(21)	(21)
<i>Cervarix</i>	86	(52)	(52)	3	50	50	28	(7)	(3)	42	21	24	13	(87)	(89)
<i>Fluarix, FluLaval</i>	22	83	83	6	>100	>100	(2)	-	-	14	63	75	4	-	(20)
Hepatitis	309	(5)	(3)	127	(5)	(3)	98	(4)	(2)	60	(3)	(2)	24	(8)	(8)
<i>Infanrix, Pediarix</i>	396	14	16	110	19	21	199	5	9	56	56	56	31	3	3
<i>Rotarix</i>	167	(1)	(1)	52	6	8	27	35	35	68	(9)	(9)	20	(19)	(23)
<i>Synflorix</i>	164	(8)	(6)	-	-	-	24	15	20	137	(11)	(9)	3	-	-
Other*	208	(9)	(6)	-	-	-	95	2	6	86	(25)	(25)	27	44	50
	9,776	-	-	3,486	(1)	1	2,562	(2)	1	2,324	5	5	1,404	(5)	(13)
ViiV Healthcare (HIV)	657	(5)	(3)	-	-	-	-	-	-	-	-	-	-	-	-
	10,433	(1)	-	-	-	-	-	-	-	-	-	-	-	-	-

ViiV Healthcare turnover
Three months ended 30 June 2013

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Combivir</i>	27	(45)	(45)	6	19	23	10	(43)	(40)	9	(60)	(60)	2	(50)	(50)
<i>Epivir</i>	11	(21)	(21)	1	(6)	(4)	5	(34)	(30)	4	(8)	(8)	1	-	(50)
<i>Epzicom/Kivexa</i>	193	13	16	63	6	8	84	14	19	23	35	35	23	20	15
<i>Selzentry</i>	35	10	13	15	5	8	17	10	16	2	1	1	1	-	50
<i>Trizivir</i>	23	(24)	(21)	13	(16)	(14)	8	(22)	(18)	1	-	(76)	1	(100)	-
<i>Other*</i>	50	(14)	(12)	21	(23)	(27)	12	-	15	11	(15)	(15)	6	-	(60)
	339	(4)	(2)	119	(4)	(1)	136	(1)	5	50	(17)	(15)	34	3	(3)

* All other product sales totalled £986 million and declined 1% CER and increased 3% AR in the quarter.

Six months ended 30 June 2013

	Total			USA			Europe			EMAP			Rest of World		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
<i>Combivir</i>	60	(29)	(28)	17	91	95	24	(33)	(31)	16	(52)	(51)	3	(33)	(50)
<i>Epivir</i>	22	(19)	(19)	4	17	20	9	(31)	(29)	6	(15)	(13)	3	(19)	(25)
<i>Epzicom/Kivexa</i>	362	10	11	124	3	5	161	10	13	36	39	42	41	13	5
<i>Selzentry</i>	72	18	20	28	4	6	32	10	14	4	>100	100	8	>100	>100
<i>Trizivir</i>	47	(18)	(16)	27	(12)	(10)	17	(18)	(16)	1	(70)	(71)	2	(67)	(33)
<i>Other*</i>	94	(28)	(27)	45	(38)	(37)	24	(23)	(23)	16	(6)	(11)	9	(11)	-
	657	(5)	(3)	245	(7)	(5)	267	(3)	-	79	(11)	(9)	66	8	2

* All other product sales totalled £1,891 million and declined 9% CER and 1% AR in the six months.